IGF1R and breast cancer: Preclinical studies have demonstrated that several dual IGF-1R/IR tyrosine kinase inhibitors (TKIs), such as OSI-906 (linsitinib), BMS-554417, and BMS-754807, show anti-proliferative and pro-apoptotic effects in BC cells [163,164].